Artelo Biosciences says Phase 1 FABP5 inhibitor ART26.12 study shows linoleic acid signaling link across disease models

Artelo Biosciences Inc

ARTL

0.00

Artelo Biosciences presented multi-omics findings at the ICRS 2026 symposium on its Phase 1 FABP5 inhibitor ART26.12.
Analysis across multiple disease models showed a consistent effect on linoleic acid-related inflammatory lipid signaling, supporting a shared mechanism across indications.
Company framed the results as strengthening the therapeutic rationale for FABP5 inhibition, with potential strategic relevance for partnering discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300857PRIMZONEFULLFEED9754672) on June 30, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.